The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses and Airway Inflammation in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma

• Status: Unknown status
• Trial end date: 2019-12-01

Summary

This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma. The study will consist of two identical study periods of 12 treatment days each, separated by a washout period of at least 3 weeks (and no more than 7 weeks). Approximately 36 eligible subjects will be enrolled, to yield 32 evaluable subjects who will be treated with both FP-025 (400 mg BID) or matching placebo in a cross-over design from the evening of Day 1 till the morning of Day 12 (22 doses per study period in total).

• Phase: Phase 2

Details

• Lead Sponsor: Foresee Pharmaceuticals Co., Ltd.